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SUMMARY  42 
Background 43 
Vascular-targeted photodynamic therapy (VTP), a novel tissue-preserving treatment for low-44 
risk prostate cancer (PC), has shown favorable safety and efficacy results in single-arm Phase 45 
I and II studies. This report presents results of a randomised, controlled, parallel-group 46 
clinical trial of padeliporfin VTP versus the standard of care, active surveillance (AS). 47 
Methods 48 
Men with low-risk, localised PC (no Gleason patterns 4 or 5) and no previous treatment were 49 
recruited from March 8, 2011 to April 30, 2013 at 47 European university centres and 50 
community hospitals.  They were randomised (stratification by centre using balanced blocks) 51 
to VTP or AS. VTP consisted of 4 mg/kg padeliporfin administered intravenously over ten 52 
minutes via optical fibres inserted into the prostate to cover the desired treatment zone and 53 
subsequent activation by laser light for 22 minutes and 15 seconds. Both groups were 54 
followed-up for 24 months in accordance with best AS practice at the time of study design, 55 
i.e., biopsy at 12-month intervals and prostate-specific antigen measurement and digital rectal 56 
exam at 3-month intervals. The prespecified co-primary efficacy endpoints were histological 57 
progression of cancer and absence of any histology result definitively positive for cancer at 58 
Month 24.  Treatment was open-label, but primary efficacy outcomes were evaluated in a 59 
blinded manner. 60 
Findings 61 
Of the 206 subjects randomised to VTP, 196 received treatment. At completion of the trial, 62 
all 413 randomised subjects (intention-to-treat population) were analysed for efficacy. VTP 63 
doubled time to progression (from 14·1 [95% CI: 12.9 to 23.8] months to 28·3 [95% CI: 26.0 64 
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to 30.6] months; p<0·0001) and reduced the progression rate to approximately one-third that 65 
of AS (adjusted hazard ratio = 0·34; 95% CI: 0·24, 0·46; p<0·0001). VTP increased the 66 
probability of a negative prostate biopsy at 24 months post-treatment from 13·5% (28 of 207 67 
subjects) to 49·0% (101 of 206 subjects) (adjusted risk ratio: 3·67; 95% CI: 2·53, 5·33); 68 
p<0·0001).  69 
VTP was well tolerated. Genitourinary function showed transient deterioration in the VTP 70 
group, but no significant effects were seen at Month 24. The most common AEs in the VTP 71 
group were urinary tract infections (21 subjects) and AEs in the renal and urinary disorders 72 
(133 subjects) and reproductive system and breast disorders system organ classes (121 73 
subjects). The most common serious side effect was retention of urine. Typically this event 74 
occurred on the first attempt to withdraw the urinary catheter (day-1 post-op). This was 75 
managed with immediate re-catheterization. The timing of a second attempt at removal of the 76 
urinary catheter was left to the discretion of the local investigator. This event occurred in 15 77 
subjects, was severe in 3 subjects, and resolved within two months in all cases.   78 
Interpretation 79 
Padeliporfin VTP is a safe effective treatment for low-risk, localised PC that reduces the rate 80 
of histological progression compared to AS. It may allow more men to consider a tissue-81 
preserving approach and defer or avoid radical therapy.  82 
Funding 83 
STEBA Biotech S.A.   84 
Registration 85 
ClinicalTrials.gov NCT01310894 86 
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 87 
RESEARCH IN CONTEXT 88 
Evidence before this study 89 
The idea of modifying our therapeutic target from the host organ to the tumour plus a margin 90 
has been the mainstay of surgical oncology during the latter half of the 20th century. The 91 
principle is probably best exemplified in breast cancer, for which the previous standard of 92 
care, the Halsted radical mastectomy, has, with time and accumulating evidence, largely been 93 
replaced by breast preservation achieved by local excision with or without radiotherapy. We 94 
have seen the same process in renal cancer. Radical nephrectomy is currently performed only 95 
when partial nephrectomy and nephron preservation is neither practical nor possible. Ten 96 
years ago it was performed in all patients. The principles behind this transition are 97 
equivalence in terms of cancer-related outcomes but better function, greater patient 98 
acceptability, quicker recovery, and enhanced survivorship. Prostate cancer (PC) is the only 99 
solid organ cancer left for which this principle is not generally applied. Over the last decade 100 
several proof-of-concept studies of focal therapy for PC have been published, but they have 101 
typically been single-centre, small, and of relatively low quality. Having said this, these 102 
studies demonstrated the feasibility of more targeted treatment for PC and more importantly 103 
suggested high levels of patient acceptability because of excellent functional outcomes. More 104 
recently we have seen registered prospective development studies and formal Phase I and 105 
Phase II studies that demonstrate both safety and early (short-term) oncological efficacy. 106 
These studies have been summarised in Valerio’s systematic review.   107 
Added value of this study 108 
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Valerio’s systematic review identified the need for comparative studies. To our knowledge, 109 
ours is the first such study. Because vascular-targeted photodynamic therapy (VTP) is an 110 
intervention involving both a drug (in this case, padeliporfin) and a device (laser light 111 
introduced into the prostate), it was subject to regulatory approval as a drug through the 112 
European Medicines Agency (EMA). A pivotal comparative study was thus necessary but 113 
was challenging to design in a manner that would be acceptable to both patients and 114 
clinicians and in which the same primary outcome could be assessed for both VTP and the 115 
comparator. We had three options for the comparator: surgery, radiotherapy, or active 116 
surveillance (AS). The first two were problematic in arriving at a primary outcome that could 117 
be applied to both the experimental arm and the control. Surgery (radical prostatectomy) 118 
would not be suitable for a biopsy-based outcome because there would be no prostate to 119 
biopsy. Radiotherapy, on the other hand, would be amenable to a protocol-required biopsy, 120 
but the histological outcome would be confounded by the necessary neoadjuvant and 121 
adjuvant androgen suppression that comprises the standard of care. Therefore, AS was the 122 
only comparator that could reasonably be employed over the intended time frame of the 123 
study. The task for the EMA and the PCM301 Study Group was to determine the upper and 124 
lower risk thresholds of this low-risk group that would define the upper and lower bounds of 125 
the study entry criteria. These criteria had the effect of excluding, within the limits of 126 
precision of the diagnostic methods available to us at the time, men that were at very low risk 127 
and therefore unlikely to progress and men that were at higher risk and therefore unlikely to 128 
be offered or indeed consent to AS.  129 
These thresholds of low risk were in keeping with standard practice at the time of study 130 
design. Recent publications from Scandinavia and Canada on mature AS populations have 131 
subsequently shown that men towards the upper threshold of low-risk PC do fare worse in 132 
progression than men with very-low-risk disease. Modern diagnostic methods, including 133 
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magnetic resonance imaging, allow us to identify these risk groups with considerably greater 134 
precision today than was possible at the time when the study was being considered by the 135 
EMA. Our results show that men with localised, low-risk PC can be treated in a way that not 136 
only preserves their genitourinary function but also results in a lower progression rate, greater 137 
chance of being declared disease-free, and reduction in need for whole-gland radical therapy 138 
in the form of surgery or radiotherapy.   139 
Implications of all the available evidence 140 
When this study was designed, our risk stratification methods at diagnosis were poor. The 141 
correction that was applied to mitigate the consequences of this imprecision was to offer 142 
radical therapy to nearly all men, irrespective of attributed risk. Today we attribute risk with 143 
greater precision using risk calculators, biomarkers, and imaging. Our study adds 144 
considerable weight to the argument that we need to move away from a one-size-fits-all 145 
approach to treatment and gradually replace it with a more risk-stratified approach to care. 146 
We have AS for men at very low risk. We have radical therapy and multimodality treatments 147 
for men at high risk for whom the consequences of treatment are matched by benefit. 148 
Between these two extremes, we now have VTP, an intervention that preserves prostate tissue 149 
when it is both possible and practical to do so. Given the precision of today’s risk 150 
stratification, future research will need to explore both the patient preferences and the upper 151 
threshold of risk (as defined by tumour grade, volume, location, multiplicity) that should 152 
determine where the transition point exists where tissue preservation is likely to confer 153 
diminishing returns and should be supplanted by whole-gland radical therapy.    154 
 155 
INTRODUCTION 156 
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Active surveillance (AS), a policy of delayed selective intervention, is an appropriate 157 
therapeutic option for low-risk prostate cancer (PC) that helps to mitigate the consequences 158 
of overtreatment.1 Most studies—though admittedly single-centre and noncomparative—have 159 
demonstrated favorable outcomes, but AS has been associated with fairly high intervention 160 
rates especially in cohorts with less stringent eligibility criteria.2 Intervention, or crossover to 161 
radical treatment (surgery or radiotherapy) or systemic therapy (androgen suppression), tends 162 
to be driven by—in descending order of frequency—pathological upgrading on repeat biopsy, 163 
biochemical progression, and patient choice.3  164 
Focal therapy and AS are both tissue-preserving strategies. They share the goal of preserving 165 
prostate tissue and consequently function by delaying or avoiding radical whole-gland 166 
treatment in men in whom it is safe to do so.4 However, focal therapy differs from AS in that 167 
it treats disease—by the process of selective tissue ablation—above a certain risk threshold 168 
and monitors disease below that threshold, as the latter is deemed to be clinically 169 
insignificant. A risk-stratified clinical pathway that offers men focal therapy in a manner 170 
complementary to AS might result in two potential benefits: a reduction in the probability of 171 
failure or crossover to radical therapy and an increase in the proportion of men eligible and 172 
willing to undergo a tissue-preserving treatment.  173 
Neither focal therapy nor AS has previously been assessed in a prospective, comparative 174 
efficacy study. Both have been assessed only in single-centre series,2,5,6 in which the 175 
outcomes were dependent on the population studied, the diagnostic precision at baseline, the 176 
intensity and manner of the reclassification tests, and the study duration. These limitations 177 
challenge informed decision-making by the patient because the attributes that are most likely 178 
to influence treatment selection are the failure rates and toxicity profiles of the two 179 
approaches and the likelihood of avoiding radical therapy. We present the results of what is to 180 
our knowledge both the first prospective comparative evaluation of the efficacy and safety of 181 
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focal therapy and the first evaluation of AS in a comparative setting—rather surprisingly 182 
given that it is a recommended standard of care. The selective ablation in our focal therapy 183 
arm was achieved using vascular-targeted photodynamic therapy (VTP) with padeliporfin, an 184 
agent that achieves its tissue effects nonthermally and had previously been evaluated in both 185 
preclinical and clinical settings.7,8  186 
METHODS 187 
Study design and participants 188 
Study CLIN1001 PCM301 was a randomised, controlled, parallel-group clinical trial of 189 
padeliporfin VTP versus AS for treatment of low-risk, localised PC. Men aged ≥18 years 190 
with low-risk, localised PC diagnosed by transrectal ultrasound (TRUS)-guided biopsy and 191 
no previous treatment were enrolled, provided they were eligible to be exposed to a 192 
photosensitising agent and had no contraindications to undergoing magnetic resonance 193 
imaging (MRI).  Participants were required to have low-risk PC but not very–low-risk PC. 194 
Men were eligible if one core of cancer that was free of Gleason patterns 4 or 5 was present 195 
provided that the cancer core length was between 3 and 5 mm. In other words, if only one 196 
core was positive, only Gleason pattern 3 was permitted but in order to qualify the cancer 197 
core length had to be greater than or equal to 3mm and less than or equal to 5mm. Men with 2 198 
or 3 cores positive were also permitted, but cancer core length could not exceed 5 mm. 199 
Clinical stage was limited to ≤T2a (pathological or radiological up to T2c disease permitted), 200 
prostate-specific antigen (PSA) ≤10 ng/mL, and prostate volume ≥25 and <70 cc). These 201 
criteria were based on a study of prediction determinants prediction in AS subsequently 202 
reported by Welty et al.9   The performance status of the subjects was not a criterion for study 203 
inclusion.  Instead, two overarching requirements had to be satisfied: men had to have a 204 
predicted life expectancy of 10 years or more and, in addition, had to be free of any medical 205 
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conditions that were deemed to be a contraindication to general anaesthesia.  Men with a 206 
contraindication to MRI (e.g. cardiac pacemaker), factors excluding accurate reading of 207 
pelvic MRI (e.g. bilateral hip replacements), or any condition or history of illness or surgery 208 
that may have posed an additional risk to men undergoing VTP procedure were excluded. 209 
Criteria for subject removal from the study were occurrence of a serious adverse event (SAE) 210 
if recommended by the investigator, subject withdrawal, or a major protocol violation. 211 
 212 
The study was conducted in compliance with Good Clinical Practice and according to a 213 
written protocol approved by each centre’s ethics committee. All subjects provided written 214 
informed consent. The trial was completed in accordance with the protocol. 215 
 216 
Randomisation and masking 217 
Investigators enrolled subjects and allocated them to the VTP and AS groups in a 1:1 ratio 218 
using a web-based randomisation system generated by the sponsor and stratified by centre 219 
using balanced blocks of varied size (2 or 4 subjects).  Treatment was open-label (subjects 220 
and investigational site staff were not blinded to study treatment), but primary efficacy 221 
outcomes were evaluated in a blinded manner. 222 
Procedures 223 
AS was conducted according to best practice at the time of study design.10,11 It comprised a 224 
protocol-directed biopsy at 12-month intervals and 3-monthly PSA measurement coupled 225 
with a digital rectal exam.  226 
The aim of VTP was to treat a complete prostate lobe. Subjects randomised to padeliporfin 227 
VTP underwent pretreatment multiparametric MRI, which was centrally reviewed with the 228 
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biopsy results by a committee composed of radiologists and urologists who made detailed 229 
recommendations on the number, length, and position of interstitial optical fibres using 230 
treatment guidance software.8,12 The treatment-guidance software was used to generate a 231 
light-density index (LDI; a measure of the energy exposure per unit volume of target tissue) 232 
of >1, which had been associated with a high probability of a single-lobe ablation in earlier 233 
studies.8 However, the urologist in charge of the treatment was allowed to adapt the treatment 234 
recommendations to the actual volume and shape of the prostate observed on the TRUS 235 
images at the time of the procedure.  Once the fibres were accurately positioned in the 236 
prostate to cover the desired treatment zone, 4 mg/kg padeliporfin (Aptuit Glasgow Ltd, 237 
Glasgow, UK) was administered intravenously over ten minutes. The drug was activated in 238 
the treatment zone by laser light at 753 nm with a fixed power of 150 mW/cm over 239 
22 minutes and 15 seconds, corresponding to an energy dose of 200 J/cm.13 Subjects with 240 
bilateral cancer received a second procedure for contralateral lobe treatment. Retreatment of 241 
lobes positive for PC at the Month 12 biopsy was permitted.  The VTP procedure was carried 242 
out under a general anaesthetic during a 2-hour operating theatre allocation with a planned 243 
overnight stay. The urethral catheter was removed the morning after the procedure.  244 
For subjects in both groups, PSA was measured and digital rectal examination performed 245 
every three months. TRUS-guided, 12-core biopsy (6 cores directed to each prostate lobe) 246 
was performed at Months 12 and 24. Thus, the sampling density (number of cores per unit 247 
volume of tissue) in the subjects who received VTP was greater than in those in the AS 248 
group, particularly for VTP-treated lobe(s) with reduced volume associated with post-249 
treatment fibrosis. Biopsy samples were read centrally by an independent pathologist blinded 250 
to treatment assignment and local pathologist reading. An independent, blinded Outcomes 251 
Review Panel reviewed all PSA data and TRUS-guided biopsy reports to assess these results 252 
and determined the number and location of positive cores. In the case of discrepancy between 253 
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the local and central biopsy readings, the panel’s pathologist adjudicated. Any additional 254 
radical PC treatments, metastases, evidence of T3 disease, and severe PC-related events were 255 
recorded at Months 12 and 24.  Any man who underwent radical PC treatment without 256 
histological progression (because of patient or physician preference) continued in the study 257 
until the end (Month 24) and returned to standard care after that. 258 
The International Prostate Symptom Score (IPSS) and International Index of Erectile 259 
Function – 15 Questions (IIEF-15) questionnaires were administered every three months 260 
through Month 12 and at Month 24 (and at seven days postprocedure for subjects who 261 
received padeliporfin VTP). Validity and sensitivity of these questionnaires to detect change 262 
in genitourinary function have been established.14,15 The EuroQol-5D (EQ-5D) questionnaire 263 
was administered at Month 12 and Month 24 to assess quality of life. All adverse events 264 
(AEs) were recorded from the signing of the consent form through the end of the study 265 
(including any occurring after the initiation of additional PC treatment). At each study visit, 266 
the investigator questioned the subject about AEs and intercurrent illnesses since his last visit. 267 
The questions were general, and the presence or absence of specific AEs was not solicited 268 
from subjects. AE severity was graded according to the National Cancer Institute Common 269 
Terminology Criteria for Adverse Events version 4.03. The investigator assessed the 270 
relationship of each AE to the study drug (padeliporfin), device, and procedure. AEs were 271 
coded and categorised according to the Medical Dictionary for Regulatory Activities 272 
(version: 18.0). Haematology, coagulation, serum chemistry, and urinalysis were evaluated 273 
every three months. Troponin was measured before discharge and quantitative D-Dimer 274 
before anaesthesia, before discharge, and at 7 days post-treatment for subjects who received 275 
VTP. Vital signs, electrocardiogram, and physical examination were performed preprocedure 276 
and postprocedure for subjects who received padeliporfin VTP. An independent Data Safety 277 
Monitoring Board (composed of two urologists, a laser surgery expert, and a statistician) 278 
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reviewed safety data and SAE reports throughout the study and advised the sponsor on 279 
matters of subject safety. 280 
Outcomes 281 
The prespecified co-primary efficacy endpoints were treatment failure (histological 282 
progression of cancer from low to moderate or higher risk over 24 months follow-up) and 283 
absence of definitive cancer (absence of any histology result definitively positive for cancer 284 
at Month 24). Moderate or higher risk was defined as the observation of one of the following 285 
events: more than three cores definitively positive for cancer when considering all 286 
histological results available during follow-up in the study, any Gleason primary or 287 
secondary pattern of 4 or more, at least one cancer core length >5 mm, PSA> 10 ng/mL in 288 
three consecutive measures, any T3 PC, metastasis, PC-related death. The prespecified 289 
secondary objective was to determine any differences between the two groups in the 290 
following outcomes: total cancer burden in the prostate; rate of additional PC radical therapy; 291 
rate of severe PC-related events (cancer extension to T3, metastasis, PC-related death); rate 292 
of AEs; rate of incontinence, erectile dysfunction, and urinary symptoms. 293 
Statistical analysis 294 
The sample size was based on an expected rate of progression from low to moderate or higher 295 
risk of ≥15% over 2 years in the AS group and 5% in the VTP group. Using these 296 
assumptions, the sample size required was 400 subjects (200 subjects per group), and at least 297 
40 events (subjects with progression of cancer) needed to be observed for the final analysis to 298 
take place. 299 
Statistical analyses were conducted using SAS version 9.3. All randomised subjects were 300 
analysed for efficacy according to assigned treatment in an intention-to-treat analysis. 301 
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Treatment failure (progression) was analysed by survival analysis. Times to progression were 302 
compared between the two treatment groups using the log-rank test and quantified using a 303 
Cox proportional-hazards regression model to derive hazard ratios at Month 24, and  304 
treatment group and age, number of positive cores, prostate volume, and disease status at 305 
baseline were used as covariates. Absence of definitive cancer (positive biopsy) was analysed 306 
as a dichotomous outcome. Proportions of subjects with observed success at Month 24 were 307 
compared by 2-sided Pearson’s chi-square test, and odds and risk ratios were calculated. 308 
Time to initiation of radical therapy was estimated by the Kaplan-Meier method, and the log-309 
rank test was used for comparison. The mean number of positive cores and maximum cancer 310 
core length at Months 12 and 24 were compared by Student t test. Other efficacy data were 311 
summarised descriptively. 312 
All subjects randomised to VTP who received any padeliporfin or initiated any study 313 
treatment-related procedure and all subjects randomised to AS were analysed for safety by 314 
treatment received. IIEF-15, IPSS, and EQ-5D results were analysed by analysis of 315 
covariance. Other safety data, including, AEs, were summarised descriptively.   316 
The trial is registered at ClinicalTrials.gov (NCT01310894). 317 
Role of the funding source 318 
The study sponsor and funder, STEBA Biotech S.A., developed the protocol in consultation 319 
with the study investigators and the European Medicines Agency (EMA). STEBA performed 320 
data management and statistical analysis and provided medical writing support for this report. 321 
AAzzouzi and ME had full access to all data in the study. The final decision to submit this 322 
report for publication was made jointly by all the authors. The corresponding author (ME) 323 
had the final responsibility to submit for publication. 324 
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RESULTS 325 
Subjects were recruited from March 8, 2011 to April 30, 2013 and followed for 326 
approximately 24 months at 47 university centres at community hospitals in ten European 327 
countries (Belgium, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, 328 
Switzerland, and the United Kingdom). Tables showing investigational sites, principal 329 
investigators, and numbers enrolled at each site and in each country are included in the 330 
Appendix (pp.1-2). The study was completed on June 25, 2015, and atotal of 413 men were 331 
enrolled: 206 randomised to the VTP group and 207 to the AS group. More subjects in the 332 
AS group (n=6) than in the VTP group (n=17) withdrew consent before study completion. 333 
Although unwillingness to accept randomisation to either group was an exclusion criterion, 334 
the sponsor anticipated that subjects randomised to AS might withdraw because they had 335 
entered the study to receive active treatment. The percentage of such withdrawals was less 336 
than expected. Otherwise, study completion and reasons for withdrawal were similar between 337 
the two groups (Figure 1).   338 
Demographic and baseline disease characteristics were well balanced between the two groups 339 
and fit the profile of low‑risk PC patients (Table 1). Of the 206 subjects randomised to VTP, 340 
nine did not subsequently start the VTP procedure: three who withdrew consent, three who 341 
were excluded because for exclusion criteria (bladder cancer discovered on pretreatment 342 
MRI, previous Gleason 3+4 biopsy, history of transurethral prostate resection), one who was 343 
discontinued by the investigator because of noncompliance, one who had a myocardial 344 
infarction, and one who was claustrophobic so unable to undergo the pretreatment MRI.   345 
Of the 197 subjects who started the VTP procedure, one had an anaesthesia reaction before 346 
receipt of any padeliporfin or laser treatment. In all, 196 subjects received initial VTP (Figure 347 
1). Of these, 62 received subsequent contralateral treatment, 11 received retreatment, and two 348 
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received both contralateral treatment and retreatment. An LDI ≥1 was achieved in 252 (98%) 349 
of 254 initial treatments of a lobe. Prostate lobes that were retreated were less likely to 350 
achieve an LDI ≥ 1, although they were exposed to the same energy of 200 J/cm (appendix 351 
p.2).   352 
All 413 randomised subjects were included in the efficacy analysis (Figure 1). Padeliporfin 353 
VTP delayed progression from low-risk to moderate or higher-risk PC and reduced the 354 
probability of a positive biopsy results at Month 24 compared to AS (Table 2). Padeliporfin 355 
VTP doubled time to progression from 14·1(95% CI: 12.9 to 23.8]) months to 28·3 (95% CI: 356 
26.0 to 30.6) months (p<0·0001). The rate of progression over 24 months was reduced to 357 
approximately one-third that of AS (adjusted hazard ratio = 0·34; 95% CI: 0·24, 0·46; 358 
p<0·0001). The distribution of predefined progression criteria showed that padeliporfin VTP 359 
was efficacious against the individual parameters of the composite progression endpoint. The 360 
principal determinants of progression were Gleason grade ≥4 and increases in number of 361 
positive cores and cancer core length, which all showed substantial reduction in the 362 
padeliporfin VTP group. The regression coefficients showed no effect of treatment group or 363 
baseline characteristics. Padeliporfin VTP also increased the probability of a negative Month 364 
24 biopsy by from 13·5% (28 of 207 subjects) to 49·0% (101 of 206 subjects) (adjusted risk 365 
ratio: 3·67; 95% CI: 2·53, 5·33); p<0·0001). Eight subjects experienced a severe PC-related 366 
event within 24 months, but only one of the subjects who did have such an event (both T3 PC 367 
and metastasis) was in the VTP group. This subject was probably under-staged at study entry. 368 
His first protocol-required biopsy resulted in a Gleason upgrading that, for the purposes of 369 
the study, constituted his first—and therefore reported—progression event. Subsequent 370 
investigation revealed a locally advanced PC, and metastasis was detected on further staging 371 
investigation. VTP exposure was associated with a reduction in the rate of radical therapy 372 
compared to men allocated to AS (12 [5.8%] of 206 subjects versus 60 [29.0%] of 207 373 
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subjects; p<0·0001) and in time to radical therapy (p<0·0001) (Figure 2). For subjects whose 374 
PC did not progress during the study, padeliporfin VTP also produced clinically and 375 
statistically significant decrease compared to AS at Month 24 in all mean tumour burden 376 
parameters: total number of positive cores (0.9 vs 2.3; p<0·0001), total cancer core length 377 
(2.6 vs 6.8 mm; p<0·0001), and maximum cancer core length (1.6 vs 3.4 mm; p<0·0001). 378 
Moreover, VTP produced a stable reduction in PSA of about 3 ng/mL over the course of the 379 
study.   380 
The nine subjects randomised to VTP but who had no treatment-related procedure were 381 
excluded from the safety analysis (Figure 1). In the VTP group, IIEF-15 and IPSS 382 
assessments showed transient deterioration in erectile and urinary function, but the Month 24 383 
result was comparable between the two groups (appendix p.3). Month 24 IPSS was 6.6 384 
(standard deviation [SD]: 5.47) for VTP and 8.2 (SD: 6.47) for AS, and Month 24 IIEF-15 385 
was 15 (SD: 10.70) for VTP and 16.8 (SD: 11.17) for AS. These results show no significant 386 
effect of padeliporfin VTP on genitourinary function compared to AS. The mean EQ-5D 387 
questionnaire scores at Month 24 in both the VTP and AS groups were slightly decreased 388 
from baseline with no difference in the two groups (82.5 [SD: 12.31] in the VTP group and 389 
81.8 [SD: 12.09] in the AS group), indicating no decrease in quality of life associated with 390 
VTP at Month 24 (appendix p.2). 391 
As expected, both the incidence and severity of AEs and SAEs were higher in the VTP group 392 
than in the AS group (Table 3). Most subjects in the VTP group experienced an AE, most of 393 
which were mild or moderate in severity and self-limited. The most commonly reported AEs 394 
in the padeliporfin VTP group were urinary tract infections (23 AEs in 21 [10.7%] subjects) 395 
and AEs in the renal and urinary disorders (280 AEs in 133 [67.5%] of 197 subjects) and 396 
reproductive system and breast disorders system organ classes (197 AEs in 121 [61.4%] of 397 
197 subjects), and these AEs accounted for the largest differences between the treatment 398 
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groups. AEs related to the study drug, device, or procedure were common but generally not 399 
severe. Most of these related AEs occurred during the procedure or in the days immediately 400 
after the procedure and resolved quickly without sequelae. The reporting of pain that was 401 
thought to be related to the procedure (due to the transcutaneous needle placement, due to the 402 
swelling of the prostate or both) was captured by the term ‘perineal pain’.  This was reported 403 
by 30 (15%) men allocated to the VTP group and by 1(0.5%) man in the AS group.  404 
Three subjects experienced events that were more long-lasting: two with urethral strictures 405 
requiring endoscopic dilation and one case of urinary incontinence in a subject who had 406 
previously undergone transurethral prostatectomy (TURP). Men with a history of surgery for 407 
benign prostatic hypertrophy (including TURP) were subsequently excluded from the study 408 
(via protocol amendment 23 October 2012) for safety reasons. All other reports of 409 
incontinence were self-limited, were usually urge-related and occurred in the period after 410 
catheter withdrawal. Incontinence management was at the discretion of the investigator. The 411 
most common related SAE in the VTP group was urinary retention. Typically this event 412 
occurred on the first attempt to withdraw the urinary catheter (day-1 post-op). This was 413 
managed with immediate recatheterization. The timing of a second attempt at removal of the 414 
urinary catheter was left to the discretion of the local investigator.  All 15 retention cases 415 
resolved within two months. No subject discontinued VTP because of an AE. Three subjects 416 
discontinued the study because of AEs. One subject in the AS group developed ureteric 417 
cancer. One subject in the VTP group had an anaphylactic reaction to the anaesthesia 418 
administered at the start of the VTP procedure; he had received no padeliporfin or VTP. One 419 
subject in the VTP group died from a myocardial infarction during mountain climbing 420 
approximately eight months after padeliporfin VTP, and the investigator assessed the AE as 421 
unrelated to study drug, device, or procedure. 422 
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An independent Data and Safety Monitoring Board reviewed safety data approximately every 423 
3 months throughout the study and advised the study sponsor on matters of subject safety. At 424 
all meetings, the members unanimously agreed that no safety issues had emerged in the 425 
study. 426 
 427 
DISCUSSION 428 
VTP doubled time to progression (from 14·1 to 28·3 months), reduced the progression rate to 429 
approximately one-third that of AS, and increased the probability of a negative prostate 430 
biopsy at 24 months post-treatment from 13·5% to 49·0%. VTP was also safe and well 431 
tolerated with only minor and transient deterioration in genitourinary function. Our study has 432 
shown that partial-gland ablation by VTP influences the course of PC in the short-to-medium 433 
term. First, the proportion of men who transition from a cancer status to cancer-free status 434 
was increased. Second, the proportion of men who progress from a histologically defined 435 
low-risk status to a higher one is diminished. As a result, fewer men chose to undergo radical 436 
therapy during the study period. Moreover, these benefits were achieved safely, efficiently, 437 
and without compromising genitourinary function when assessed at 12 and 24 months after 438 
VTP.   439 
Since this is the first comparative efficacy study of its type, it is important to consider the 440 
methodological considerations that were inherent in its design and conduct. The first relates 441 
to the population studied. By today’s standards this population might be considered low risk. 442 
However, whilst the study was in development and being discussed with the EMA, neither 443 
AS nor focal therapy were accepted as standard care. The EMA agreed that we could 444 
reasonably exclude very-low-risk patients. Therefore, lower and upper thresholds of risk 445 
(defined by Gleason pattern and tumour burden) were set, below which and above which men 446 
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were excluded. This low-risk group was the only one that could have been studied at the time. 447 
Were the study designed today, given the changes to risk categorisation, it is likely that men 448 
with well characterised PC and low volume secondary Gleason pattern 4 would be included.16  449 
A second limitation relates to rapidly changing practice in risk stratification of PC patients, 450 
most significantly the use of MRI in the diagnostic and the re-evaluation phases of both AS 451 
and focal therapy.17,18 When the study began, few units offered MRI to patients on AS or as 452 
part of the work-up for focal therapy. Now it is difficult to imagine using either strategy 453 
without MRI. Although only men assigned to VTP had MRI in this study, images were used 454 
only for treatment planning, not for detection or staging. The only way in which unilateral 455 
use of MRI could have biased subjects’ allocation was the detection of colorectal or bladder 456 
cancer, which would have triggered a study withdrawal. If the study were repeated today, 457 
MRI would play an important role in subject selection and risk stratification for both 458 
interventions.19  459 
A third concern is discriminating true progression from reclassification. When using a 460 
biopsy-based strategy to refine the risk stratification at given intervals in AS, upgrading 461 
(transition from an exclusive Gleason pattern 3 status to one with elements of Gleason pattern 462 
4 or 5) occurs. Determining whether the observed increase in the Gleason pattern is a 463 
correction of inherent diagnostic imprecision or the product of true disease progression has 464 
proved challenging. Whilst no universal definition of clinical significance exists, recently 465 
published MRI studies have used the presence of Gleason pattern 4 as the minimum 466 
definition of clinically significant PC.17,18 Physicians have recommended treatment upon 467 
upgrading irrespective of its underlying cause. This strategy appears prudent given that 468 
recently published data from two mature AS series have identified higher risk groups (within 469 
the risk profile suitable for AS) that are at greater risk of progression.2,20,21  470 
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The final issue relates to the efficacy endpoints evaluated. If endpoints such as progression to 471 
metastases or death had been used, the natural history of low-risk PC would have required a 472 
very large study conducted over two decades. Some experts advocate prioritizing of shorter-473 
term, relevant outcomes that are important to patients to support patients and their physicians 474 
in their clinical decision-making.22 475 
This multicentre study has demonstrated that padeliporfin VTP can be implemented widely 476 
and delivered effectively and safely. The latter issue deserves some qualification. Exposure to 477 
VTP resulted in an increase in the frequency of SAEs from 1 in 10 men on AS to 1 in 3 men 478 
who received VTP. Most of the events were expected, genitourinary in nature, and self-479 
limited. The most important of these events was failure to void on catheter removal (urinary 480 
retention). The event was managed by replacement of the urethral catheter and extension of 481 
the period of dependent urinary drainage.   482 
It is worth noting that most study sites had no prior experience in delivering focal therapy, let 483 
alone VTP. Study recruitment was timely over a large geographical area, a scenario that 484 
contrasts with the many previous attempts to undertake randomised, comparative studies of 485 
early PC treatment, which either failed to recruit completely or closed because of poor 486 
recruitment.23 Feasibility is an important attribute for surgical interventions, and our results 487 
demonstrate that VTP can be taught, learned, and delivered by a range of health care 488 
providers and systems. This study was performed at a large number of centres and in a 489 
variety of healthcare systems, few of which had any previous experience with VTP, and yet 490 
we managed to achieve a very low rate of permanent urinary toxicity. Since our 491 
understanding and management of early PC have changed so much in the last few years, it is 492 
worth speculating on how padeliporfin VTP might be used with current diagnostics and risk 493 
stratification, which are unrecognizable from those at the time of study design. Adoption of 494 
MRI and targeted biopsy into the clinical pathway has created more precise risk stratification, 495 
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allowing a more nuanced approach to men with a new PC diagnosis. Given that MRI is now 496 
widely used within the diagnostic pathway but was not used for diagnosis or risk stratification 497 
in our study, it is worth speculating on how the diagnostic process may be influenced by the 498 
results of this study. First, it is likely that a pathway based on MRI—because of its role as a 499 
triage test between an elevated PSA and biopsy—will result in a reduction of the number of 500 
men biopsied and in the proportion of men receiving the diagnosis of clinically insignificant 501 
PC. In contrast, men with an MRI abnormality will undergo targeted biopsy (something that 502 
was not possible without MRI), resulting in a greater sensitivity for clinically significant 503 
disease. It is very likely that the men with clinically significant isolated lesions will be the 504 
candidates for focal prostate therapy. Men who do not need treatment should not have it. Men 505 
who require whole-gland treatment because of bilateral clinically significant disease should 506 
be offered it. Men with locally advanced disease should be offered multimodality therapy. 507 
However, men who have low-risk, localised disease can now choose, on the basis of the 508 
evidence that our study has generated, how to approach tissue preservation.  509 
More research is needed to address unanswered questions, the principal one being the long-510 
term effect of tissue-preserving treatment on PC control rates. One unknown element is the 511 
efficacy of padeliporfin VTP in eradicating cancers of different grades within the target 512 
volume. A study in men with Gleason pattern 4 (NCT01875393) has been submitted for 513 
publication. Another uncertainty relates to the stability of the tissue that lies beyond the 514 
treatment zone. This question requires long-term follow-up, which has been initiated in the 515 
men from Study CLIN1001 PCM301. 516 
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TABLES (IN-TEXT) 623 
Table 1.  Demographic and baseline prostate cancer characteristics 624 
Characteristic 
Padeliporfin VTP 
N = 206 
Active surveillance 
N = 207 
Total 
N = 413 
Age (years)  
Mean (SD) 64.2 (6.7) 62.9 (6.7) 63.5 (6.7) 
Range: minimum, maximum 45, 85 44, 79 44, 85 
Race  
Caucasian, n (%) 202 (98.1) 206 (99.5) 408 (98.8) 
Other, n (%) 4 (2.9) 1 (0.5) 5 (1.2) 
Body mass index (kg/m2)  
Mean (SD) 26.5 (3.3) 27.3 (4.0) 26.9 (3.7) 
Range: minimum, maximum 18.8, 38.6 18.8, 44.8 18.8, 44.8 
Time since diagnosis (months)  
Mean (SD) 6.3 (8.5) 6.0 (7.9) 6.2 (8.2) 
Range: minimum, maximum 0.2, 54.2 0.2, 47.4 0.2, 54.2 
TNM staging  
T1a, n (%) 1 (0.5) 0 1 (0.2) 
T1c, n (%) 177 (85.9) 180 (87.0) 357 (86.4) 
T2a, n (%) 28 (13.6) 27 (13.0) 55 (13.3) 
PSA (ng/mL)  
Mean (SD) 6.2 (2.1) 5.9 (2.0) 6.1 (2.1) 
Range: minimum, maximum 0.1, 10.0 0.5, 10.0 0.1, 10.0 
Estimated prostate volume (cc)  
Mean (SD) 42.5 (12.5) 42.5 (11.8) 42.5 (12.1) 
Unilateral disease, n (%) 157 (76.2) 163 (78.7) 320 (77.5) 
Bilateral disease, n (%) 49 (23.8) 44 (21.3) 93 (22.5) 
Total number of pretreatment biopsy cores  
Mean (SD) 13.6 (3.3) 13.6 (3.6) 13.6 (3.4) 
Range: minimum, maximum 10, 25 10, 26 10, 26 
Total number of pretreatment biopsy cores 
with cancer 
 
Mean (SD) 2.1 (0.7) 2.0 (0.7) 2.1 (0.7) 
Range: minimum, maximum 1, 3 1, 3 1, 3 
1 core, n (%) 39 (18.9) 52 (25.1) 91 (22.0) 
2 cores, n (%) 110 (53.4) 100 (48.3) 210 (50.8) 
3 cores, n (%) 57 (27.7) 55 (26.6) 112 (27.1) 
Total cancer core length (mm)  
Mean (SD) 4.3 (2.3) 3.8 (2.4) 4.1 (2.4) 
Range: minimum, maximum 0a, 14 0a, 11 0,14 
SD = standard deviation; TNM = tumour, nodes, metastasis; VTP = vascular-targeted photodynamic therapy. 
a  Some of the subjects included on the basis of two biopsies at the beginning of the study had one of those two biopsies negative. 
  625 
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Table 2.  Co-primary efficacy endpoints 
Endpointa 
Padeliporfin VTP 
N = 206 
n (%) 
Active surveillance 
N = 207 
n (%) 
Padeliporfin VTP vs active surveillance 
Ratio (95% CI) p value 
Progression  58 (28.2) 120 (58.0) 
Adjustedb hazard ratio 
0.34 (0.24, 0.46) 
<0·001c 
Criteria for progressiond  
More than three cores positive 23 (11.2) 58 (28.0) NC <0·001e 
Gleason ≥4 49 (23.8) 91 (44.0) NC <0·001e 
Cancer core length >5 mm 25 (12.1) 51 (24.6) NC 0·001e 
PSA >10 ng/mL in three consecutive 
measures 
3 (1.5) 14 (6.8) NC 0·007e 
Any T3 prostate cancer 0 4 (1.9) NC NA 
Metastasis 0 0 NC NA 
Prostate cancer-related death 0 0 NC NA 
Negative Biopsy at Month 24  101 (49.0) 28 (13.5) 
Adjustedf risk ratio 
3.67 (2.53, 5.33) 
<0·001e 
CI = confidence interval; NA = not applicable; NC = not calculated; VTP = vascular-targeted photodynamic therapy. 
a  The Hochberg procedure was used to adjust for multiplicity of the two co-primary endpoints.  
b  Cox proportional-hazards model with treatment as fixed effect and baseline age, number of cores positive, prostate volume, and disease status (unilateral/bilateral) 
as covariates. 
c  From the log-rank test of equality of survival curves across treatment groups Cox proportional-hazards model with treatment as fixed effect and baseline age, 
number of cores positive, prostate volume, and disease status (unilateral/bilateral as covariates. 
d  A subject might have met > 1 criterion for progression. 
e  From Pearson’s chi-square test for observed success.  
f  Logistic regression model with treatment as fixed effect and baseline age, number of cores positive, prostate volume, and disease status (unilateral/bilateral) as 
covariates. 
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Table 3.  Adverse events  
AE category 
Padeliporfin VTP 
N = 197* 
Active surveillance 
N = 207 
Subjects 
n (%) 
Events             
n 
Subjects 
n (%) 
Events            
n 
All AEs 187 (94.9) 939 114 (55.1) 307 
Drug, device, or VTP procedure-related AE 155 (78.7) 551 NA NA 
All SAEs 60 (30.5) 88 21 (10.1) 25 
Drug, device, or VTP procedure-related SAE 30 (15.2) 39 NA NA 
AE leading to study discontinuation 2 (1.0) 2 1 (0.5) 1 
AE leading to death 1 (0.5) 1 0 0 
Adverse Events Occurring in ≥ 10% of Subjects in Either Group 
System Organ Class 
Preferred Term 
Subjects 
n (%) 
Subjects 
n (%) 
Infections and infestations 
Urinary tract infection 21 (10.7) 9 (4.3) 
Renal and urinary disorders 
Dysuria 54 (27.4) 5 (2.4) 
Haematuria 56 (28.4) 6 (2.9) 
Micturition urgency 21 (10.7) 2 (1.0) 
Pollakiuria 20 (10.2) 6 (2.9) 
Urinary retention 32 (16.2) 2 (1.0) 
Reproductive system and breast disorders 
Erectile dysfunction 74 (37.6) 24 (11.6) 
Perineal pain 30 (15.2) 1 (0.5) 
Adverse Events by Severity 
AE Grade 
System Organ Class 
Preferred Term 
Subjects 
n (%) 
Subjects 
n (%) 
Grade 1 (mild) 49 (24.9) 42 (20.3) 
Grade 2 (moderate) 94 (47.7) 52 (25.1) 
Grade 3 (severe)  40 (20.3) 19 (9.2) 
Blood and lymphatic disorders 
Thrombocytopenia 1 (0.5) 0 
Cardiac disorders 
Atrial fibrillation 1 (0.5) 0 
Myocardial infarction  1 (0.5) 2 (1.0) 
Endocrine disorders 
Hypothyroidism 1 (0.5) 0 
Gastrointestinal disorders 
Abdominal pain 1 (0.5) 0 
Gastrointestinal haemorrhage 0 1 (0.5) 
Inguinal hernia 2 (1.0) 0 
Rectal haemorrhage 1 (0.5) 0 
General disorders and administration site conditions 
Device failure 1 (0.5) 0 
Pyrexia 0 1 (0.5) 
Immune system disorders 
Drug hypersensitivity 2 (1.0) 0 
Infections and infestations 
Epididymitis 1 (0.5) 0 
Orchitis 1 (0.5) 0 
Otitis externa 0 1 (0.5) 
Staphylococcal infection 0 1 (0.5) 
Urinary tract infection 2 (1.0) 2 (1.0) 
Injury, poisoning and procedural complications 
Accident 1 (0.5) 0 
Craniocerebral injury 1 (0.5) 0 
Procedural pain 0 1 (0.5) 
Investigations 
Fibrin D dimer increased 2 (1.0) 0 
Musculoskeletal and connective tissue disorders 
Arthralgia 1 (0.5) 0 
Osteoarthritis 0 1 (0.5) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 
Ear neoplasm 0 1 (0.5) 
Neuroendocrine carcinoma 1 (0.5) 0 
Prostate cancer 1 (0.5) 0 
Tongue cancer recurrent 0 1 (0.5) 
Tonsillar neoplasm 1 (0.5) 0 
Ureteric cancer metastatic 0 1 (0.5) 
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Ureteric cancer regional 0 1 (0.5) 
Nervous system disorders 
Cerebrovascular accident 1 (0.5) 0 
Headache 1 (0.5) 0 
Transient ischaemic attack 0 1 (0.5) 
Psychiatric disorders 
Depression 1 (0.5) 1 (0.5) 
Renal and urinary disorders 
Dysuria 3 (1.5) 0 
Haematuria 1 (0.5) 0 
Urinary incontinence 2 (1.0) 1 (0.5) 
Urinary retention  3 (1.5) 1 (0.5) 
Reproductive system and breast disorders 
Ejaculation failure 2 (1.0) 0 
Erectile dysfunction 2 (1.0) 3 (1.4) 
Perineal pain 1 (0.5) 0 
Prostatic pain 1 (0.5) 0 
Prostatitis 3 (1.5) 1 (0.5) 
Skin and cutaneous tissue disorders 
Purpura 1 (0.5) 0 
Surgical and medical procedures 
Aortic valve replacement 0 1 (0.5) 
Cataract operation 1 (0.5) 0 
Facial operation 1 (0.5) 0 
Knee arthroplasty 1 (0.5) 0 
Vascular disorders 
Phlebitis 0 1 (0.5) 
Thrombosis 0 1 (0.5) 
Grade 4 (life-threatening)  3 (1.5) 1 (0.5) 
Cardiac disorders 
Angina unstable 1 (0.5) 0 
Myocardial infarction 0 1 (0.5) 
Immune system disorders 
Anaphylactic reaction 1 (0.5) 0 
Respiratory, thoracic and mediastinal disorders 
Bronchospasm 1 (0.5) 0 
Grade 5 (death)  1 (0.5) 0 
Cardiac disorders 
Myocardial infarction 1 (0.5) 0 
AE = adverse event; SAE = serious adverse event; VTP = vascular-targeted photodynamic therapy. 
*  The nine subjects randomised to VTP but who had no treatment-related procedure were excluded from analysis of safety.   
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FIGURE LEGENDS (IN-TEXT) 
Figure 1.   Disposition of subjects by treatment group  
 
Figure 2.   Time to initiation of radical therapy by treatment group – Kaplan-Meier analysis  
 
